Nicholas Iannotti

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies”.

FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies

Annals of Oncology(2022)10.1016/j.annonc.2022.02.001

N/A

4.9DataRank · unranked

200 citations

Nicholas Iannotti, Martin Gutierrez, David C. Smith, Luis Féliz, Christine Lihou +5 more

Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial

Annals of Oncology(2020)10.1016/j.annonc.2020.05.012

N/A

3.1DataRank · unranked

106 citations

Sara A. Hurvitz, Jack A. Di Palma, Ron Bose, A. Jo Chien, Nicholas Iannotti +48 more